

=> b reg
FILE 'REGISTRY' ENTERED AT 11:19:02 ON 15 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2008 HIGHEST RN 1049627-95-3
DICTIONARY FILE UPDATES: 14 SEP 2008 HIGHEST RN 1049627-95-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>


=> d que sta 115
L7 STB



```
VAR G1=0/S
REP G2=(0-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L9 9009 SEA FILE=REGISTRY SSS FUL L7
1.13 STR



```

VAR G1=0/S
REP G2=(0-2) C
REP G3=(0-4) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED
ECOUNT IS F4.C F2.N AT 17

```

GRAPH ATTRIBUTES

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L15 42 SEA FILE=REGISTRY SUB=L9 SSS FUL L13

100.0% PROCESSED 461 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:19:12 ON 15 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 14 Sep 2008 (20080914/ED)

HCplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr 118 tot

L18 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:128596 HCAPLUS
 DN 148:369264
 TI New water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives
 AU Kanamitsu, Norimasa; Osaki, Takashi; Itsuji, Yutaka; Yoshimura, Masakazu;
 Itsujimoto, Hisashi; Soga, Manabu
 CS Central Research Laboratory, Maruishi Pharmaceutical Co., Ltd., 2-2-18
 Inazawa-ku, Tsurumi-ku, Osaka, 538-0042, Japan
 Chemical & Pharmaceutical Bulletin (2007), 55(12), 1682-1688
 DOI: 10.1243/0950-0340-5512-1682
 ISSN: 0950-0340
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors developed new i.v. sedative-hypnotic compds. with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. The authors synthesized approx. 170 derivs. and evaluated their hypnotic effects by i.v. administration of the compds. to mice. A series of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and their analogs (I-IV) showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HDS₅₀) of these 4 compds. when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, resp., and the LD₅₀s (LD₅₀s) were 88.67, 64.69, >120, and >120 mg/kg, resp. The therapeutic indexes (LD₅₀/HDS₅₀) were 37.73, 34.05, >55.30, and >38.46, resp., and therefore IV is being considered as the most potential candidate for clinical trials in humans.

IT 701304-01-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (uses) (isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

IT 701304-02-1P 701304-03-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (uses) (isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

IT 701304-01-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (uses) (isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

RN 701304-01-0 HCAPLUS

CN Cyclpent[fl]isoindol-1(2H-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:1261054 HCAPLUS
 DN 144:6817
 TI Phenogenics, 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them
 IN Yoshimura, Masakazu; Kanamitsu, Norimasa; Itsuji, Yutaka; Yoshimura, Masakazu; Kawashima, Motoko
 PA Maruishi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 53 pp.
 CODEN PIXX02
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2005113501	A1	20051201	2005WO-JP0009361	20050523
W: AE, AG, AL, AM, AI, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NC, NE, NG, NG, OM, PG, PR, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, VG, US, UZ, VC, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MM, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, RH, YU				
AU--2005245292	A1	20051201	2005AU-000245292	20050523
CA----2563968	A1	20051201	2005CA-0002563968	20050523
EP--1549817	A1	20051201	2005EP-0001549817	20050523
R: AE, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, RH, YU				
CN--1956955	A	20070502	2005CN-08016827	20050523
BR--2006011546	A	20080102	2006BR-00011546	20060523
MD--2006010466	A	20070702	2006MD-00010466	20060523
IN--2006IN06250	A	20071130	2006IN-0N006250	20061025
KR--2007108077	A	20070213	2006KR-000724401	20061121
US--2006PA13766	A	20070208	2006MX-PA0013766	20061124
US--20080021042	A1	20080124	2007US-US-000587367	20070717
PRAI 20080021042	A1	200804524		
2005WO-JP0009361	W	20050523		

OS MARPAT 144:6817
 GI



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) or (II) or a salt thereof or a 6-membered condensed ring containing conjugated double bond: X = halo, Cl-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxylphenyl; m = an integer of 0-2; Y = O, COR₄, cyclopentylmethyl, piperidin-1-yl; wherein R₄ = Cl-6 alkyl; X = O, R₄ or a salt thereof is selected. The compds. I possess fast analgesic and anticonvulsant properties without affecting motor function. Thus, 2-(3-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isindol-1-ylacetophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isindol-1-ylacetophenyl-1-ylacetophenyl hydrochloride 0.31, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.25 g were stirred in 40 mL THF at

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[(4-methyl-1-piperazinyl)carbonylmethyl]isoindolin-1-one. 5,6-Dimethyl-2-(4-fluorophenyl)-3-[(4-methyl-1-piperazinyl)carbonylmethyl]isoindolin-1-one monohydrate and its salt showed analgesic effect on mice at 30 mg/kg p.o. in 5 min after administration and required a lower dosage than gabapentin. (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A tablet formulation contng. II was described.

IT 701304-01-0P 701304-04-3P 701304-06-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (uses)

(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compds. containing them)


IT 701304-01-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (uses)

(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compds. containing them)

RN 701304-01-0 HCAPLUS

CN Cyclpent[fl]isoindol-1(2H-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:467859 HCAPLUS
 DN 141:38525
 TI Preparation of isoindoline derivatives as narcotic drugs
 IN Toyooka, Toshiaki; Kanamitsu, Norimasa; Yoshimura, Masakazu; Kuriyama, Naoko; Tamura, Takashi
 PA Maruishi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 88 pp.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2004048335	A1	200404830	2003WO-IPD014886	20031125
W: AE, AG, AL, AM, AI, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, MA, MD, MG, MM, MN, ME, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SZ, TJ, TM, TZ, UG, ZM, ZW				
RM: BW, GH, GM, KE, LS, MM, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, RH, YU				

OS MARPAT 141:38525
 GI



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2004048335	A1	200404610	2003WO-0002434669	20031125
AU--200324669	A	20040418	2003AU-000234669	20031125
JP--2004189733	A	20040708	2003JP-000393809	20031125
EP--1566378	A1	20050824	2003EP-000774195	20031125

R: AE, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, RH, YU

BR--20030166659

CN----1741995

A 20060301 2003CN-080109198

NZ----529834

A 20070831 2003NE-000539834

IN--2005IN01967

A 20070713 2005IN-DN0001967

US--20050022329

A1 20060303 2005US-000534414

MO--20050022329

A 20060303 2005MO-000900259


GI

PRAI 2002JP-000342399

A 20021126 2003WO-JP0014986

OS MARPAT 141:38525

GI



AB The title compds. I (wherein R1 = 1 to 3 alkyl or alkoxy; or a ring attached to benzene ring; X = O or S; R2 = (un)substituted Ph, PhCH₂, pyridyl, etc.; L = 1-8; with proviso) or salts thereof therefrom are prepared as narcotic drugs. For example, the compd. I¹HCl was prepared in a multi-step synthesis. Some of the steps are shown in the scheme and some are in ref.

IT 701304-01-0P 701304-02-1P 701304-03-2P

701304-04-3P 701304-05-4P 701304-06-5P


701304-22-5P 701304-23-6P 701304-24-7P

701304-25-8P 701304-26-9P 701304-27-0P

701304-28-1P 701304-29-2P 701304-30-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (Uses)
 IT 701304-01-0P
 (drug candidate; prepn. of isoindoline derivs. as narcotic drugs)
 RI: PN: (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 RN 701304-01-0 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxethyl]- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 534414


=> d bib abs hitstr l19 tot

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:128596 HCAPLUS
 DN 148:369264
 TI New water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives
 AU Kanamori, Norimasa; Osaki, Takashi; Itsuji, Yutaka; Yoshimura, Masakazu;
 Tsujimoto, Hisashi; Soga, Manabu
 CS Central Research Laboratory, Maruishi Pharmaceutical Co., Ltd., 2-2-18
 Inazu-naka, Tsurumi-ku, Osaka, 538-0042, Japan
 SO Chemical & Pharmaceutical Bulletin (2007), 55(12), 1682-1688
 CPN CPTIAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors developed new i.v. sedative-hypnotic compds. with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. The authors synthesized approx. 170 derivs. and evaluated their hypnotic effects by i.v. administration of the compds. to mice. A series of 1-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-3-(2-phenyl-1-one analogs (I-IV) showed potent sedative-hypnotic acts with a good water-solubility and a wide safety margin. The hypnotic doses (HD50s) of these compds. when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, resp., and the LD₅₀ (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, resp. The therapeutic index (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, resp. Among these, IV is being considered as the most potential candidate for clin. trials in humans.
 IT 870234-68-7P 1013427-48-9P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 870234-68-7 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-, (-) - (CA INDEX NAME)


Rotation (-).



RN 1013427-48-9 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-2-phenyl-, (-) - (CA INDEX NAME)

Rotation (-).

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:268409 HCAPLUS
 DN 144:312115
 TI Preparation of 3-(piperazinylcarbonylmethyl)isoindole derivatives and anesthetic and sedative compositions containing them
 AU Kanamori, Norimasa; Itsuji, Hiroshi; Osaki, Takashi; Tsujimoto, Hisashi; Inoue, Keiji
 PA Maruishi Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 20 pp.
 CDTN: JXXXF
 DP Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP-2006026913	A	20060323	2004JP-000262082	20040909
PPAI 2004JP-000262082				
OS MARPAT 144:312115				

GI




AB Claimed are the derivs. I (R1 = Me, 2 R1 groups are bonded to form C2-4 alkylene; R2 = OH, Cl-5 saturated aliphatic hydrocarbyl or C3-6 unsatd. hydrocarbyl substituted with 1-alkoxy or 2-1-H, halide, and their salts). The compds. claimed I (alcohol and capsule) are also claimed. The compds. are used by i.v. dosing for induction and maintenance of general anesthesia, management of sedation after operation in intensive care, etc. Thus, 5,6-indandicarboxylic anhydride (preparation given) was reacted with 1-(4-carboxyphenyl)-3-(2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-(3-fluorophenyl)-3-hydroxy-3,5,6,7-tetrahydrocyclopent[f]isoindol-1(2H)-one) was reacted with (carboethoxymethylene)triphenylphosphorane to give 2-(2-(3-fluorophenyl)-3-oxo-2,3,5,6,7-hexahydrocyclopent[f]isoindol-1(2H)-one-3-acid. This was resolved to the salt form with (S)-1-(2-methyl-2-propenyl)piperazine and the (-)-isomer (0.15 g) was amided with 1-(2-methyl-2-propenyl)piperazine to give 0.15 g (-)-I [R1R1 = (CH2)3, R2 = CH2CMe:CH2, X = 3-F]. Similarly prepared (-)-I.HCl [R1R1 = (CH2)3, R2 = CH2CMe:CH2, X = 3-F] showed anesthetic activity with HD50 (min. dose to induce ≥30 s loss of righting reflex in 50% mice) of 1.77 mg/kg vs. 14.72 mg/kg of propofol.

IT 879895-96-2P 879895-97-3P 879895-98-4P
 879895-99-5P 879896-00-1P 879896-01-2P
 879896-02-3P 879896-03-4P 879896-04-5P
 879896-05-6P
 RL: PH (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (piperazinylcarbonylmethyl)isoindole derivs. and i.v. anesthetic and sedative compns. containing them)

RN 879895-96-2 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-(2-methyl-2-propenyl-1-piperazinyl)-2-oxoethyl)-, (-) - (CA INDEX NAME)


Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 879895-97-3 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propenyl-1-piperazinyl)-2-oxoethyl)-2-phenyl)-, hydrochloride (1:1), (-) - (CA INDEX NAME)


Rotation (-).



● HCl


RN 879895-98-4 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propenyl-1-piperazinyl)-2-oxoethyl)-2-phenyl)-, hydrochloride (1:1), (-) - (CA INDEX NAME)

Rotation (-).




RN 879895-99-5 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propenyl-1-piperazinyl)-2-oxoethyl)-2-phenyl)-, (-) - (CA INDEX NAME)

Rotation (-).



RN 879896-00-1 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl)-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HCl

RN 879896-01-2 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-(2-methoxyethyl)-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HCl

RN 879896-02-3 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-(2-hydroxyethyl)-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)-


Rotation (-).



● HCl

RN 879896-03-4 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-oxopropyl)-1-piperazinyl]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl

RN 879896-04-5 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-(4-(2,2-dimethoxyethyl)-1-piperazinyl)-2-oxoethyl]-2-(3-fluorophenyl)-3,5,6,7-tetrahydro-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl



● HCl

RN 879896-05-6 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-(4-(2-methyl-2-propen-1-yl)-1-piperazinyl)-2-oxoethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).




● HCl

AN 20051261054 HCAPLUS
DN 144:6317
TI Preparation of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them
IN Yoshimura, Masakazu; Kanamitsu, Norimasa; Itsuji, Yutaka; Osaki, Takashi; Kawashima, Motoko
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
COPEN: PIXX22

DT PCT
LA Japanese
FAN,CNT 1
PATENT NO. KIN# DATE APPLICATION NO. DATE
PI WO-2005113501 A1 20051201 2005WO-P000361 20050523
M: AE, AG, AL, AM, AJ, AU, AZ, BA, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NE, NF, NL, OM, PG, PR, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY, TJ, TM, TN, TR, TZ, UA, VE, VN, US, US, VC, VN, YU,
ZA, ZM, ZW
RM: BW, GH, GM, KE, LS, MU, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, IQ, GW, MU,
MR, NE, SN, TD, TZ
CN: BM, BR, CG, CY, CS, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU
CN----1956955 A 20070502 2005CN-00016837 20050523
BR----2005011546 A 20080102 2005BR-00011546 20050523
EP----19569486 A 20070522 2005EP-00016838 20050523
IN-2006IN00450 A 20070522 2006IN-DN006820 20060523
KR-2007018077 A 20070213 2006KR-000724401 20061121
MX-2006PA13766 A 20070203 2006MX-PA0013766 20061124
US-20080021042 A1 20080124 2007US-000587367 20070717


PRA1 20040151596 A 20040524 2005AU-000245292 20050523
2005WO-P000361 W 20050523
OS MARPAT 144:6317
GI



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = C1-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2 or a 6-membered condensed ring containing two heteroatoms, or a 5-membered heterocyclic ring containing one Ph group to which X is bonded from 3,4-methylenedioxyphenyl; m = an integer of 0-2; Y = O, COR4, cyclopropylmethyl, piperidin-1-yl; wherein R4 = C1-4 alkyl; X = O, S or a salt thereof is disclosed. The compds. I possess fast analgesic activity against capsaicin-induced pain and anti-inflammatory effect on motor function. Thus, 2-(3-fluorophenyl)-3-[4-(2-methoxyethyl)-5,6-dimethyl-3,4-dihydro-2,3-dihydro-1H-isindolin-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at 25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[(4-methyl-1-piperazinyl)-2-(3-methoxypropyl)-1-piperazinyl]carbonyl-1-methylisindolin-1-one hydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 5 min after administration and required lower dosage than gabapentin.
 (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A tablet formulation contg. II was described.
 IT 870171-13-4P 870171-21-4P 870171-23-6P
 870171-23-8P 870171-30-5P 870171-32-7P
 870171-34-9P
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); B1OL (Biological study); PREP (Preparation); USES (Uses);
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)
 RN 870171-13-4 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)


Rotation (-).



● HC1

RN 870171-15-6 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propen-1-yl)-1-piperazinyl)ethyl)-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 870171-17-8 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propyn-1-yl)-1-piperazinyl)ethyl)-2-phenyl-, (-)- (CA INDEX NAME)


Rotation (-).




L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 870171-30-5 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propen-1-yl)-1-piperazinyl)ethyl)-2-phenyl- (CA INDEX NAME)



RN 870171-32-7 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-(2-oxo-2-(4-(2-propyn-1-yl)-1-piperazinyl)ethyl)-2-phenyl- (CA INDEX NAME)




RN 870171-34-9 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-(4-cyclopropylmethyl)-1-piperazinyl]-2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 870171-19-0 HCAPLUS
 CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-(4-cyclopropylmethyl)-1-piperazinyl]-2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl-, (-)- (CA INDEX NAME)


Rotation (-).




RN 870171-21-4 HCAPLUS
 CN 5H-1,3-Dioxolol[4,5-f]isoindol-5-one, 6,7-dihydro-7-(2-oxo-2-(4-(2-propen-1-yl)-1-piperazinyl)ethyl)-6-phenyl- (CA INDEX NAME)



RN 870171-23-6 HCAPLUS
 CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-(2-(4-methyl-1-piperazinyl)-2-oxoethyl)-6-phenyl- (CA INDEX NAME)



RN 870171-25-8 HCAPLUS
 CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-(2-oxo-2-(4-(2-propen-1-yl)-1-piperazinyl)ethyl)-6-phenyl- (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)



FILE 'USPATOLD' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 120 tot

L20 ANSWER 1 OF 2 USPATFULL on STN
 AN 2008:23861 USPATFULL
 TI Composition For Controlling Neuropathic Pain
 IN Makoto, Yoshimura, Kobe-shi, Hyogo, JAPAN
 PA MARUISHI PHARMACEUTICAL CO., LTD., Osaka-shi, Osaka, JAPAN, 541-0044
 (non-U.S. corporation)
 PI US-20080021042 A1 20080124
 AI 2005US-000587367 A1 20050523 (11)
 2005US-000589361 20050523
 20070717 PCT 371 date
 PPAI 2004JP-000153206 20040524
 DT UTILITY
 FS APPLICATION
 LREP HAMME, SCHUMANN, MUELLER & LARSON, P.C., P.O. BOX 2902, MINNEAPOLIS, MN,
 55401-0902
 CLMN Number of Claims: 15
 ECL Exemplary Claim: 1-11
 DRWN 8 Drawing Page(s)
 LN.CNT 860
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The instant application provides a pharmaceutical composition for
 controlling neuropathic pain, which comprises a compound of formula:
 ##STR1## or a salt thereof.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The instant application provides a pharmaceutical composition for
 controlling neuropathic pain, which comprises a compound of formula:
 ##STR1## or a salt thereof.
 IT 701304-01-0P 701304-04-3P 701304-06-5P
 870171-13-4P 870171-15-6P 870171-17-8P
 870171-19-0P 870171-21-4P 870171-23-6P
 870171-25-8P 870171-30-5P 870171-32-7P
 870171-34-9P
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
 pain control agent compns. containing them)
 IT 701304-03-0P
 (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
 pain control agent compns. containing them)
 RN 701304-01-0 USPATFULL
 CN Cyclopent[if]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)

L20 ANSWER 2 OF 2 USPATFULL on STN
 AN 2006:61222 USPATFULL
 TI Isoindoline derivative
 IN Takashi, Kondo, Osaka-fu, JAPAN
 LN. 1-11, Norina, Takanishi-shi, JAPAN
 Yoshimura, Masakazu, Hyogo-ken, JAPAN
 Kuriyama, Haruo, Osaka-fu, JAPAN
 Tamura, Takashi, Osaka-fu, JAPAN
 MARUISHI PHARMACEUTICAL CO., LTD (non-U.S. corporation)
 PI US-20060053392 A1 20060124
 2003JP-000524414 A1 20031125 (10)
 2003W0-00014986 20031125
 20050511 PCT 371 date
 PPAI 2002JP-000342399 20021126
 DT
 FS APPLICATION
 LREP FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC,
 20007, US
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1971
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Provided is a novel isoindoline compound of the formula (I): ##STR1#
 The compound is useful for anesthesia by inducing sedation in a mammal.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 701304-01-0P 701304-02-1P 701304-03-2P
 701304-04-3P 701304-05-4P 701304-06-5P
 701304-07-6P 701304-23-6P 701304-24-7P
 701304-25-8P 701304-26-9P 701304-27-0P
 701304-32-7P
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 IT 701304-01-0P
 (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
 RN 701304-01-0 USPATFULL
 CN Cyclopent[if]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
 (4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:46:28 ON 15 SEP 2008)

FILE 'HCAPLUS' ENTERED AT 10:46:39 ON 15 SEP 2008
L1 1 US20060052392 /PN

FILE 'REGISTRY' ENTERED AT 10:47:02 ON 15 SEP 2008

FILE 'HCAPLUS' ENTERED AT 10:47:02 ON 15 SEP 2008
L2 TRA L1 1- RN : 284 TERMS

FILE 'REGISTRY' ENTERED AT 10:47:03 ON 15 SEP 2008
L3 284 SEA L2
L4 254 L3 AND NRS>=2
L5 17 L4 AND NRRS>=3
SAV TEM J414C4/A L***
L6 STR L***
L7 STR L***
L8 32 L7
L9 9009 L7 FULL
SAV TEM J414C4/A L9
L10 17 L9 AND L3
L11 13 L10 AND NC2NC2/ES
L12 8992 L9 NOT L10-11
L13 STR L6
L14 0 L13 SAM SUB=L9
L15 42 L13 FULL SUB=L9
L16 13 L15 AND L3
L17 29 L15 NOT L16

FILE 'HCAPLUS' ENTERED AT 11:18:03 ON 15 SEP 2008
L18 3 L16
L19 3 L17

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:18:10 ON 15 SEP 2008
L20 2 L16-17

FILE 'HCAOLD' ENTERED AT 11:18:38 ON 15 SEP 2008
L21 0 L16
L22 0 L17

=>